Review

Characteristics and Roles of T Follicular Helper Cells in SARS-CoV-2 Vaccine Response

Xuyang Chi¹,†, Jia Gu¹,† and Xiaoxue Ma¹,2,*

¹ Department of Pediatrics, The First Hospital of China Medical University, Shenyang 110001, China
² Department of Microbiology & Immunology and Pediatrics, Dalhousie University, and Canadian Center for Vaccinology, IWK Health Centre, Halifax, NS B3K 6R8, Canada
* Correspondence: snow1999521@126.com; Tel.: +86-024-83282527
† These authors contributed equally to this work.

Abstract: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination is critical to controlling the coronavirus disease 2019 (COVID-19) pandemic. However, a weak response to the vaccine and insufficient persistence of specific antibodies may threaten the global impact of mass vaccination campaigns. This study summarizes the internal factors of the body that affect the effectiveness of the SARS-CoV-2 vaccine. T follicular helper (Tfh) cells support germinal center B cells to produce vaccine-specific immunoglobulins. A reduction in the Tfh cell number and a shift in the subset phenotypes caused by multiple factors may impair the production and persistence of high-affinity antibodies. Besides efficacy differences caused by the different types of vaccines, the factors that affect vaccine effectiveness by intervening in the Tfh cell response also include age-related defects, the polarity of the body microenvironment, repeated immunization, immunodeficiency, and immunosuppressive treatments. Assessing the phenotypic distribution and activation levels of Tfh cell subsets after vaccination is helpful in predicting vaccine responses and may identify potential targets for improving vaccine effectiveness.

Keywords: SARS-CoV-2; vaccine; Tfh cells; immunoglobulin

1. Introduction

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a large global disease outbreak and the coronavirus disease 2019 (COVID-19) pandemic. There have been over 540 million confirmed cases and close to 6.3 million deaths worldwide (https://covid19.who.int, accessed on 1 August 2022). The pandemic has caused serious financial, socio-economical, and political problems. Although specific drugs to treat SARS-CoV-2 have been identified, vaccination is still urgently needed to limit the spread of the disease and prevent severe cases.

Vaccination is now an indispensable medical intervention that has saved millions of lives. Most SARS-CoV-2 vaccines have been studied in phase III clinical trials, the efficacy against COVID-19 is almost more than 50%, and the protective effect against symptomatic and asymptomatic infections is high [1]. However, with the popularization of vaccines, people are aware of many potential problems. The production of vaccine-specific antibodies and the durability of acquired immunity are often not satisfactory, such that booster vaccines are required. Therefore, many people refuse to be vaccinated, bringing new public health problems.

Vaccines provide protection by generating specific antibodies. Accumulating evidence shows that T follicular helper (Tfh) cells play a fundamental role in the humoral immune response after vaccination and support the production of immunoglobulins (Ig) by B cells [2,3]. Therefore, it is not difficult to understand the role of the Tfh cells in the pathogenesis of SARS-CoV-2 infection and the COVID-19 vaccines [4–7]. However, how to regulate the function of Tfh cells to improve the effectiveness of the SARS-CoV-2 vaccines
and the persistence of immunoglobulin production specific to SARS-CoV-2 has yet to be studied. In this review, we summarize the role of Tfh cells in mediating antibody production and the recent findings on the relationship between Tfh cells and the effectiveness of vaccines. We also discuss how to improve the effectiveness of the SARS-CoV-2 vaccines by regulating Tfh cells.

2. Tfh Cells Supporting Immunoglobulin Production

Tfh cells were first identified in human tonsils [8]. These cells support the activation of B cells, generation of plasma cells, and antibody responses in the germinal center (GC). B-cell lymphoma-6 (Bcl-6) is the main transcription factor of Tfh cells and promotes the expression of C-X-C chemokine receptor type 5 (CXCR5) [9–11]. CXCR5 is specifically expressed on the surface of Tfh cells and works as an attractant for B cell follicles to make intercellular contacts with B cells. Tfh cells produce interleukin (IL)-21 to promote the maturation of B cells and the production of antibodies [8].

Tfh cells are known for their high flexibility and plasticity [12]. While expressing Bcl-6, these cells can simultaneously express the transcription factors of other T helper (Th) cell subgroups, such as T-box factor (T-bet) for Th1 cells, GATA-binding protein 3 (GATA3) for Th2 cells, or retinoic-acid-receptor-related orphan nuclear receptor gamma (RORγT) for Th17 cells. We define these biphenotypic cells as different Tfh cell subsets, called Tfh1 cells, Tfh2 cells, and Tfh17 cells, respectively [12]. Each Tfh cell subset follows different developmental pathways due to environmental stimuli, resulting in functional heterogeneity. The functional diversity of Tfh cell subsets supports the isotype switching of GC B cells to induce different types of immunoglobulins [12].

3. Different Immunoglobulins Are Promoted by Tfh Cell Subsets

The immunoglobulin family contains five classes (IgM, IgA, IgE, IgG, and IgD) with different properties and functions [13]. IgM is the first immunoglobulin expressed during B cell development and is associated with primary immune responses. IgA is essential for protecting mucosal surfaces from toxins, viruses, and bacteria. IgE participates in hypersensitivity, allergic reactions, and reactions to parasitic infections. IgG is functionally divided into four subclasses, IgG1, IgG2, IgG3, and IgG4, and plays a crucial role in antiviral and vaccine responses. IgD is found at very low levels with a short serum half-life; its function is unclear [13] (Figure 1).

![Figure 1](image-url)  
**Figure 1.** Tfh cell subsets support the production of immunoglobulins with different functions. Pre-Tfh (pTfh) cells can differentiate into Tfh1, Tfh2, or Tfh17 phenotypes under different microenvironmental conditions due to different physiological or pathological states. Each Tfh cell subset is functionally specific and can mediate B cell differentiation to produce different types of immunoglobulins that participate in various immune responses.
3.1. Tfh1 Cells Induce IgG1 and IgG2 Production after Infection and Vaccination

IgG1 is the most abundant immunoglobulin subclass, representing 60–70% of the total IgG [14]. IgG1 deficiency accounts for about 30% of all immunoglobulin deficiency diseases, leading to the aggravation of infection [15]. IgG1 mainly reacts to protein antigens, especially from viruses and vaccines [16,17]. During viral infection or after vaccination, interferons are secreted in large quantities, and the type I immune response is activated, resulting in the expansion of Tfh1 cells. Increased Tfh1 cells promote GC B cells to produce IgG1 [18,19]. In addition, pathological increases in IL-21 secretion and Tfh1 cell differentiation have been observed in some autoimmune diseases, such as systemic lupus erythematosus [20].

The IgG2 subclass accounts for 20–30% of total IgG, with an average concentration of 3 mg/mL in adult serum. IgG2 reacts to encapsulated bacteria and plays a key role in the humoral response towards polysaccharide antigens [14]. In interferon-deficient mice, the differentiation of Tfh1 cells is impaired, leading to a decrease in GC B cells and IgG2a production [21–23].

3.2. Tfh2 Cells Induce IgG4 and IgE in Allergic Responses

The IgG4 subclass accounts for only 5% of the total IgG [14]. IgG4-related disease is a newly discovered allergic disease characterized by increased serum IgG4 levels and the infiltration of IgG4+ plasma cells into tissues [24]. A study showed that, compared to the control group, the frequency of Tfh2 cells was significantly increased in patients with IgG4-related disease and positively correlated with the serum levels of IgG4 and IL-4 [25].

IgE binds to the high-affinity receptor FcεRI2 expressed on the surface of mast cells and basophils, and crosslinks allergens, resulting in cell activation and the release of allergy mediators [26]. Tfh2 cells can promote B cell class conversion and induce IgE production [27]. In a mouse model of allergic asthma, allergens could mediate a type II immune response and the activation of Tfh2 cells [28,29]. Tfh cell deficiency can lead to a significant decrease in IgE production [30].

3.3. Tfh2 and Tfh17 Cells Promote IgA Secretion in Mucosal Immunity

The level of IgA in serum is lower than IgG, while secretory IgA is much higher on the surface of mucous membranes [4]. Secretory IgA can prevent pathogens from invading the mucosa [31]. Intestinal Peyer patches (PPs) are important lymphoid organs that produce secretory IgA to support the stabilization of the intestinal mucosal immunity [32]. Tfh17 cells have the potential to convert to Tfh cells in the PPs and support the production of IgA in the gut [33]. Abnormal deposition of serum glycosylated IgA1 on the walls of small vessels leads to IgA vasculitis (IgAV) [34,35]. A recent study showed that Tfh2 and Tfh17 cells increased in patients with IgAV compared to the control group and decreased during disease remission. Moreover, the frequencies of circulating Tfh2 cells and Tfh17 cells were positively correlated with serum IgA levels in IgAV [36]. However, the microenvironment conditions conducive to Tfh17 differentiation are still unclear.

4. Tfh Cell Response in SARS-CoV-2 Infection

Tfh cells protect against infectious diseases by promoting antibody responses to viral, bacterial, parasitic, and fungal infections [8]. Although it is possible to produce antibodies against SARS-CoV-2 in the absence of Tfh cells, optimal protection in vivo still relies on Tfh cells to produce high-affinity antibodies [37]. Studies suggest that Tfh cells promote GC responses and drive B cell differentiation to produce high-quality neutralizing antibodies, which is necessary to control SARS-CoV-2 infection [38]. Increased numbers of spike (S)-specific antibodies, memory B cells, and activated circulating Tfh (cTfh) cells, along with IgM and IgG antibodies bound to SARS-CoV-2 were detected in the blood of patients with mild and convalescent COVID-19 and the lymphonodus of rhesus monkeys infected with SARS-CoV-2 [39–41]. Lipsitch et al. found that cross-reactive memory Tfh cells can trigger faster and better antibody responses, accelerating the control of upper respiratory tract and
lung viruses [42]. Moreover, IgG antibodies, neutralizing plasma cells, memory B cells, and memory T cells specific to SARS-CoV-2 are continuously produced by recovered patients for at least three months after infection and the receptor-binding domain-specific memory B cells and S-specific memory B cells increase over time [43,44]. Furthermore, virally infected Th1 polarization conditions usually increase cTfh1 cells in humans and rhesus monkeys infected with SARS-CoV-2 [40,41,45–47].

A general deficiency of T and B cells in lung tissues and dysregulation of the humoral immune response have been found in patients who died from COVID-19. Compared to focal tissue pneumonia, the formation of Tfh cells and reproductive centers were largely absent in the draining lymph nodes of late COVID-19 patients [47]. Kaneko et al. analyzed the thoracic lymph nodes and spleens of patients who died from acute SARS-CoV-2 infections and found that although these patients had a strong T-cell-mediated B cell response, the GCs were significantly deficient [49]. Long-lasting GCs can produce a long-term memory immune response and produce high-quality antibodies after exposure to antigens [50]. In the absence of GCs, Tfh cells are not generated to activate GC B cells. Non-GC B cell responses cannot induce long-term memory or the production of high-quality antibodies. Therefore, Tfh cells are required for the GC B cell response to SARS-CoV-2 infection [49].

5. Tfh Cell Responses in SARS-CoV-2 Vaccination

Due to the prominent function of Tfh cells in promoting B cell maturation and immunoglobulin production, these cells may play an important role in vaccine-mediated acquired immunity. Researchers evaluated the phenotypes of T cells from individuals who received the BNT162b2 mRNA vaccine and found that the S-specific Tfh cells in the blood peaked one week after the second immunization but persisted at nearly constant frequencies in the axillary lymph nodes for at least six months [52]. The frequencies of the Tfh cells in lymph nodes are associated with antigen-specific GC B Cells [52]. Moreover, immunocompromised individuals (e.g., kidney transplant recipients) fail to produce Tfh cells, demonstrating a defect in GC B cell responses specific to SARS-CoV-2 after vaccination [52]. Cavazzoni et al. disrupted the generation of Tfh cells in mice vaccinated with the SARS-CoV-2 spike protein vaccine and found that the frequency of GC B cells decreased by about 50%, indicating that Tfh cells are critical for a strong GC response [53].

In contrast, the expansion of Tfh cells may help improve the strength of the GC response and vaccine effectiveness. Alameh et al. suggested that lipid nanoparticle (LNP) preparations with intrinsic adjuvant activity could induce Tfh cells, GC B cells, long-lived plasma cells, and memory B cells, and increase the production of persistent, protective antibodies [54]. In addition, antigen re-exposure can establish and recall SARS-CoV-2 spike epitope-specific CD4+ T cell memory and induce the accumulation of Tfh cells, which may contribute to long-term protection against SARS-CoV-2 [55].

6. Factors Affecting Vaccine Effectiveness by Regulating Tfh Cell Responses

Because sufficient induction of the Tfh cell response is essential for the effectiveness of vaccines, it is necessary to identify the factors that affect the Tfh cell response after vaccination. In addition to the type of vaccine and adjuvant, the age, body microenvironment, and basic immune status of the vaccinees may also affect the Tfh cell response and alter the vaccine effect (Figure 2).
6.1. Age-Dependent Immune Response

Although the Tfh B cell responses in vaccinees can be generally activated, the degree of activation varies among different populations. Studies have shown that the effectiveness of a vaccine is related to the age of the vaccinees. In a prospective longitudinal cohort study, antibody responses after the first vaccination with the BNT162b2 mRNA vaccine were inversely proportional to age, and the antibody response was significantly higher in younger people than in older people [56]. A second dose of the vaccine can trigger high concentrations of IgG antibodies in the elderly population; however, these antibodies have weaker neutralization capacities [56].

Live-attenuated influenza vaccine can induce Tfh cell activation and long-term antibody responses in children; however, these effects are less in adults [57]. In a study of the 2014–2015 trivalent seasonal influenza vaccination in different age groups, there was a five-fold reduction in vaccine-specific antibodies in the serum of older adults compared to younger adults. The study showed that the deficiency in antibody production was associated with decreasing cTfh cells in the aged [58]. In aged mouse experiments, a reduction in Tfh cell responses was associated with the impaired T cell initiation induced by conventional type 2 dendritic cells (cDC2s). Treatment with Toll-like receptor 7 agonists can increase the number of antigen-carrying cDC2s and boost Tfh cell response in aged mice [58]. Therefore, we suggest that age may affect the Tfh cell response and vaccine effects, and age-related defects can be reversed by agonists.

6.2. Polarity of Tfh Cells Affects the Vaccine Effect

The dominant cytokine milieu at the earliest stage of differentiation determines the heterogeneity of the phenotype and function of Tfh cells. Thus, the body microenvironment may affect the role of terminal Tfh cells with different phenotypes in the immune response [12]. The Tfh1 subset causes isotype switching of GC B cells to produce IgG1, the major immunoglobulin for antiviral effects [12]. Therefore, a body microenvironment that promotes the differentiation of Tfh1 cells but not Tfh2 or Tfh17 cells would be conducive to high vaccine effectiveness.

After SARS-CoV-2 vaccination, there is an increase in the numbers of Tfh and Tfh1 cells in the peripheral blood of vaccinees [59]. Lederer et al. reported that SARS-CoV-2 mRNA vaccines could induce a stronger immune response than the rRBD-AddaVax vaccine.
Moreover, they observed that bona fide Tfh cells induced by SARS-CoV-2 mRNA vaccines had a mixed Th1-Th2 functional profile, while rRBD-AddaVax triggered a Th2-skewed Tfh cell profile [60].

Nevertheless, a study of the low response to hepatitis B vaccination showed that although the number of total circulating Tfh cells was significantly lower in low responders, it was not due to an insufficient Tfh1 subpopulation. In contrast, cTfh2 and cTfh17 cells were severely shifted toward a cTfh1 phenotype in low responders [61]. Moreover, they demonstrated that miR-19b-1 and miR-92a-1 were associated with cTfh cell subset distribution and antibody production [61]. Above all, the shifts in Tfh cell subsets were closely associated with protective antibody response production. Thus, an increase in total Tfh cells alone may not be sufficient to improve antibody responses.

6.3. Initial Immune Status of Vaccines and Tfh Cell Responses

Many studies have confirmed that immunocompromised patients have a very high risk of developing COVID-19 disease and dying after contracting SARS-CoV-2 [62–65]. It is critical to protect these patients against COVID-19 by effective SARS-CoV-2 vaccination. Hagin et al. assessed the immunogenicity of the BNT162b2 vaccine in twenty-six patients with congenital immunodeficiency (IEI), eighteen of whom could produce a vaccine-specific antibody response after two doses of the vaccine [66]. Four of the patients were unable to achieve seroconversion. Delmonte et al. conducted a large study in which 85% of IEI patients had detectable antibodies after immunization; however, their antibody titers were significantly lower than healthy controls [67]. In acquired immunodeficiency, patients with advanced HIV infection also have a lower response to mRNA vaccination [68,69].

In most patients with autoimmune or autoinflammatory disease, the mRNA BNTb262 vaccine is immunogenic with a reliable safety profile. In patients treated with anti-CD20 or mycophenolate mofetil, BNT162b2-induced immunogenicity is significantly suppressed [70]. Moreover, it has been reported that, compared to control groups, the Tfh cell response after SARS-CoV-2 mRNA vaccination was lower in patients with multiple sclerosis who received anti-CD20 therapy [71]. Consequently, immune deficiency and treatment with immunosuppressants can attenuate Tfh cell responses, thereby reducing the effectiveness of vaccines.

6.4. Repeated Immunization Enhances the Intensity of the Tfh Cell Response

Repeated immunization with booster vaccines can improve the responsiveness of vaccinees by enhancing the Tfh cell response [55]. In a study of healthy subjects both naïve to and recovered from SARS-CoV-2 (recovered subjects monitored before and after mRNA prime and boost vaccination), all subjects naïve to SARS-CoV-2 showed robust T cell responses after the first dose of the vaccine that was further enhanced by the second dose [72]. In comparison, subjects who had recovered from SARS-CoV-2 had maximal T cell responses after the first vaccine dose, with little additional T cell boosting after the second dose [72].

Studies have shown that a subset of patients who failed to achieve seroconversion or had a low response after two mRNA vaccine doses responded to a third vaccine dose [73,74]. Kamar et al. [75] studied a cohort of thirty-seven solid organ transplant recipients, including thirty-one patients who had no response to the first three vaccine doses and five patients who responded weakly. Thirteen patients who did not respond to the first three doses were seroconverted with the fourth dose. Moreover, the fourth vaccine dose increased median antibody concentrations from 4 BAU/mL to 402 BAU/mL for the five patients who responded weakly to the first three vaccine doses [75].

6.5. Types of Vaccines and Inoculated Species

Studies have shown that the effects of vaccines vary according to the inoculated species. The NVX-CoV2373 vaccine, a SARS-CoV-2 subunit vaccine from the full-length spike protein, can elicit multifunctional CD4+ and CD8+ T cells, Tfh cells, and antigen-specific GC
B cells in the spleens of mice [76]. SARS-CoV-2 spike and receptor-binding domain (RBD) immunogens produce robust B and Tfh cell responses in macaques. However, the spike protein subunit vaccine, not the RBD protein subunit vaccine, is potently immunogenic in mice [77]. In contrast, a protein subunit vaccine composed of the spike ectodomain protein (StriFK) plus a nitrogen bisphosphonate-modified zinc-aluminum hybrid adjuvant (FH002C) can generate substantially higher neutralizing antibody titers in mice, hamsters, and cynomolgus monkeys [78]. Compared to a recombinant protein vaccine formulated with the MF59-like adjuvant, a single immunization with SARS-CoV-2 mRNA elicited potent Tfh cell and GC B responses with superior activity specific to SARS-CoV-2 in mice [59]. The mRNA-1273 vaccine provided rapid protection in the upper and lower airways from SARS-CoV-2 infection in rhesus macaques by inducing Th1 and Tfh cell responses and eliciting robust SARS-CoV-2 neutralizing activity [79].

The results from clinical trials indicated that multiple inactivated SARS-CoV-2 vaccines, including BBIBP-CorV, CoronaVac, and BBV152, were safe, well-tolerated, and could induce satisfactory high neutralizing antibody titers to reduce the number of severe cases [80–83]. The BNT162b2 SARS-CoV-2 mRNA vaccine significantly increased cTfh cells, and the frequency of cTfh cells was positively correlated with anti-S-specific IgA and IgG antibody titers [84]. Tfh cell responses according to the specific vaccines are shown in Table 1.

### Table 1. Tfh cell responses to various types of SARS-CoV-2 vaccines.

| Vaccine Types                          | Species                  | Location                       | Tfh-Related Response                                                                 | Antibody                  | Reference |
|----------------------------------------|--------------------------|--------------------------------|---------------------------------------------------------------------------------------|---------------------------|-----------|
| NVX-CoV2373 protein vaccine            | mice, baboons            | blood, spleen                  | Elicits multifunctional CD4\(^+\) and CD8\(^+\) T cells, Tfh cells, and antigen-specific GC B cells | IgG                       | [75]      |
| Spike protein subunit vaccine and Receptor-Binding Domain protein subunit vaccine | macaques                 | blood, lymph node              | Elicits potent antibody responses and serum neutralizing activity                      | IgG                       | [76]      |
| Spike protein subunit vaccine          | mice                     | blood, lymph node              | Elicits robust GC B cell and Tfh cell responses                                       | IgG                       | [76]      |
| StriFK-FH002C protein vaccine          | mice, hamsters, cynomolgus monkeys | blood, lymph node | Generates substantially higher neutralizing antibody titers                           | IgG, IgG1, IgG2a, IgG2b   | [77]      |
| Protein vaccine formulated with MF59-like adjuvant | mice | blood                           | Triggers Th2-skewed Tfh cell profile                                                  | IgG1                      | [59]      |
| BBIBP-CorV protein vaccine             | human                    | blood                          | Induces rapid, robust humoral responses                                               | No data                   | [79]      |
| CoronaVac protein vaccine              | human                    | blood                          | Induces rapid, robust humoral responses                                               | IgG                       | [80]      |
| BBV152 protein vaccine                 | human                    | blood                          | Induces high neutralizing antibody responses; enhances humoral and cell-mediated immune responses | IgG                       | [82]      |
| SARS-CoV-2 mRNA vaccine                | mice                     | blood, lymph node, bone marrow, spleen | Elicits potent GC B and Tfh cell responses with superior ability specific to SARS-CoV-2 | IgG1, IgG2a, IgG2b        | [59]      |
| mRNA-1273 vaccine                     | rhesus macaques          | blood, lung                    | Induces Th1 and Tfh cell responses; elicits robust SARS-CoV-2 neutralizing activity   | IgA, IgG                  | [78]      |
| BNT162b2 mRNA vaccine                  | human                    | blood                          | Induces cTfh cells; the frequency of cTfh cells is positively correlated with anti-Spike-specific IgA and IgG antibody titers | IgA, IgG                  | [83]      |
7. Discussion

The persistence of the humoral response induced by the SARS-CoV-2 natural infection is relatively limited, and herd immunity to COVID-19 may be difficult to achieve through natural infection [85]. Therefore, we urgently need to control the epidemic through extensive SARS-CoV-2 vaccination. The effectiveness of the vaccine not only directly affects the anti-infection ability of the vaccinators but also indirectly affects the vaccination willingness and the vaccination rate of the population. We believe that Tfh cell activation levels can reflect vaccine effectiveness. Detecting the Tfh cell response after vaccination can predict the production of long-term high-affinity antibodies. Any factor that interferes with this response may potentially change the effectiveness of the vaccine. Factors that regulate the Tfh cell response may be potential targets for improving vaccine efficacy.

Author Contributions: X.M. and X.C. created the research concept and designed and wrote the manuscript. J.G. designed and drew diagrams and revised the manuscript. All authors contributed to the article and approved the submitted version. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by the National Natural Science Foundation of China (grant 81901658), the Liaoning Province Natural Science Foundation (2022-BS-134), the Infection, Immunity, Inflammation & Vaccinology (IIV) Dalhousie Medical Research Foundation (DMRF), the Dr. David H. Hubel Postdoctoral Fellowship program, and the Nova Scotia COVID-19 Health Research Coalition (PI) Canada.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Fiolet, T.; Kherabi, Y.; MacDonald, C.J.; Ghosn, J.; Peiffer-Smadja, N. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review. Clin. Microbiol. Infect. 2022, 28, 202–221. [CrossRef] [PubMed]
2. Breitfeld, D.; Ohl, L.; Kremmer, E.; Ellwart, J.; Sallusto, F.; Lipp, M.; Forster, R. Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production. J. Exp. Med. 2000, 192, 1545–1552. [CrossRef]
3. Schäerli, P.; Willimann, K.; Lang, A.B.; Lipp, M.; Loetscher, P.; Moser, B. CXC chemokine receptor 5 expression defines follicular homing T cells with B cell helper function. J. Exp. Med. 2000, 192, 1553–1562. [CrossRef] [PubMed]
4. Juno, J.A.; Hill, D.L. T follicular helper cells and their impact on humoral responses during pathogen and vaccine challenge. Curr. Opin. Immunol. 2022, 74, 112–117. [CrossRef] [PubMed]
5. Baumjohann, D.; Fazilleau, N. Antigen-dependent multistep differentiation of T follicular helper cells and its role in SARS-CoV-2 infection and vaccination. Eur. J. Immunol. 2021, 51, 1325–1333. [CrossRef] [PubMed]
6. Cui, D.; Tang, Y.; Jiang, Q.; Jiang, D.; Zhang, Y.; Lv, Y.; Xu, D.; Wu, J.; Xie, J.; Wen, C.; et al. Follicular Helper T Cells in the Immunopathogenesis of SARS-CoV-2 Infection. Front. Immunol. 2021, 12, 731100. [CrossRef] [PubMed]
7. Wang, Y.; Tian, Q.; Ye, L. The Differentiation and Maintenance of SARS-CoV-2-Specific Follicular Helper T Cells. Front. Cell. Infect. Microbiol. 2022, 12, 953022. [CrossRef] [PubMed]
8. Crotty, S. T Follicular Helper Cell Biology: A Decade of Discovery and Diseases. Immunity 2019, 50, 1132–1148. [CrossRef] [PubMed]
9. Nurieva, R.I.; Chung, Y.; Martinez, G.J.; Yang, X.O.; Tanaka, S.; Matskevitch, T.D.; Wang, Y.H.; Dong, C. Bcl6 mediates the development of T follicular helper cells. Science 2009, 325, 1001–1005. [CrossRef]
10. Yu, D.; Rao, S.; Tsai, L.M.; Lee, S.K.; He, Y.; Sutcliffe, E.L.; Srivastava, M.; Linterman, M.; Zheng, L.; Simpson, N.; et al. The transcriptional repressor Bcl-6 directs T follicular helper cell lineage commitment. Immunity 2009, 31, 457–468. [CrossRef]
11. Johnston, R.J.; Pooholek, A.C.; DiToro, D.; Yusuf, I.; Eto, D.; Barnett, B.; Dent, A.L.; Craft, J.; Crotty, S. Bcl6 and Blimp-1 are reciprocal and antagonistic regulators of T follicular helper cell differentiation. Science 2009, 325, 1006–1010. [CrossRef] [PubMed]
12. Ma, X.; Nakayamada, S. Multi-Source Pathways of T Follicular Helper Cell Differentiation. Front. Immunol. 2021, 12, 621105. [CrossRef] [PubMed]
13. Schroeder, H.W., Jr.; Cavacini, L. Structure and function of immunoglobulins. J. Allergy Clin. Immunol. 2010, 125, S41–S52. [CrossRef] [PubMed]
14. Batten, M.; Ramamoorthy, N.; Kljavin, N.M.; Ma, C.S.; Cox, J.H.; Dengler, H.S.; Danilenko, D.M.; Caplazi, P.; Wong, M.; Fulcher, D.A.; et al. IL-27 supports germinal center function by enhancing IL-21 production and the function of T follicular helper cells. J. Exp. Med. 2010, 207, 2895–2906. [CrossRef] [PubMed]

15. Sigal, I.H. Basic science for the clinician 38: IgG subclases. J. Clin. Rheumatol. 2012, 18, 316–318. [CrossRef]

16. Perreau, M.; Savoye, A.L.; Cubus, R.; Demengeot, J.; Steinmetz, O.M.; Stockinger, B. Plasticity of Th17 cells in Peyer’s patches is responsible for the induction of T follicular helper cells and germinal centers. Immunity 2012, 37, 880–892. [CrossRef] [PubMed]

17. Cubus, R.A.; Mudd, J.C.; Savoye, A.L.; Perreau, M.; van Grevenynghe, J.; Metcaif, T.; Connick, E.; Meditz, A.; Freeman, G.J.; Abesada-Terk, G., Jr.; et al. Inadequate T follicular cell help impairs B cell immunity during HIV infection. Nat. Med. 2013, 19, 494–499. [CrossRef] [PubMed]

18. Ballesteros-Tato, A.; Randall, T.D.; Lund, F.E.; Spolski, R.; Leonard, W.J.; Leon, B. T Follicular Helper Cell Plasticity Shapes immune homeostasis. J. Exp. Med. 2014, 207, 49–56. [CrossRef] [PubMed]

19. Shaded, K.C.; Conroy, M.E.; Washburn, N.; Kitaoka, M.; Huynh, D.J.; Laprise, E.; Patil, S.U.; Shreffler, W.G.; Anthony, R.M. Sialylation of immunoglobulin E is a determinant of allergic pathogenicity. Nature 2020, 582, 265–270. [CrossRef] [PubMed]

20. Yao, Y.; Chen, C.L.; Yu, D.; Liu, Z. Roles of follicular helper and regulatory T cells in allergic diseases and allergen immunotherapy. Allergy 2021, 76, 456–470. [CrossRef] [PubMed]

21. Croquet, J.M.; Schujs, M.J.; Smyth, M.J.; Deswarte, K.; Beyearet, R.; Braun, H.; Boon, L.; Karlsson Hedestam, G.B.; Nutt, S.L.; Hammad, H.; et al. Interleukin-21-Producing CD4(+) T Cells Promote Type 2 Immunity to House Dust Mites. Immunity 2015, 43, 318–330. [CrossRef] [PubMed]

22. Ballesteros-Tato, A.; Randall, T.D.; Lund, F.E.; Spolski, R.; Leonard, W.J.; Leon, B. T Follicular Helper Cell Plasticity Shapes Pathogenic T Helper 2 Cell-Mediated Immunity to Inhaled House Dust Mite. Immunity 2016, 44, 259–273. [CrossRef] [PubMed]

23. Kobayashi, T.; Iijima, K.; Dent, A.L.; Kita, H. Follicular helper T cells mediate IgE antibody response to airborne allergens. J. Allergy Clin. Immunol. 2017, 139, 300–313 e307. [CrossRef] [PubMed]

24. Hand, T.W.; Reboldi, A. Production and Function of Immunoglobulin A. Annu. Rev. Immunol. 2021, 39, 695–718. [CrossRef] [PubMed]

25. Kato, L.M.; Kawamoto, S.; Maruya, M.; Fagarasan, S. Gut TFH and IgA: Key players for regulation of bacterial communities and immune homeostasis. Immunol. Cell Biol. 2014, 92, 49–56. [CrossRef] [PubMed]

26. Hirota, K.; Turner, J.E.; Villa, M.; Duarte, J.H.; Demengeot, J.; Steinmetz, O.M.; Stockinger, B. Plasticity of Th17 cells in Peyer’s patches is responsible for the induction of T cell-dependent IgA responses. Nat. Immunol. 2013, 14, 372–379. [CrossRef] [PubMed]

27. Davin, J.C.; Coppo, R. Henoch-Schonlein purpura nephritis in children. Nat. Rev. Nephrol. 2014, 10, 563–573. [CrossRef] [PubMed]

28. Nir, Y.; Lee, S.K.; Silva, D.G.; Martin, J.L.; Pratama, A.; Hu, X.; Chang, P.; Walters, G.; Vinuesa, C.G. Interferon-gamma excess leads to pathogenic accumulation of follicular helper T cells and germinal centers. Science 1999, 289, 1742–1745. [CrossRef] [PubMed]

29. Batten, M.; Ramamoorthy, N.; Kljavin, N.M.; Ma, C.S.; Cox, J.H.; Dengler, H.S.; Danilenko, D.M.; Caplazi, P.; Wong, M.; Fulcher, D.A.; et al. IL-27 supports germinal center function by enhancing IL-21 production and the function of T follicular helper cells. J. Exp. Med. 2010, 207, 2895–2906. [CrossRef] [PubMed]

30. Sigal, I.H. Basic science for the clinician 38: IgG subclases. J. Clin. Rheumatol. 2012, 18, 316–318. [CrossRef]

31. Hand, T.W.; Reboldi, A. Production and Function of Immunoglobulin A. Annu. Rev. Immunol. 2021, 39, 695–718. [CrossRef] [PubMed]

32. Kato, L.M.; Kawamoto, S.; Maruya, M.; Fagarasan, S. Gut TFH and IgA: Key players for regulation of bacterial communities and immune homeostasis. Immunol. Cell Biol. 2014, 92, 49–56. [CrossRef] [PubMed]

33. Hirota, K.; Turner, J.E.; Villa, M.; Duarte, J.H.; Demengeot, J.; Steinmetz, O.M.; Stockinger, B. Plasticity of Th17 cells in Peyer’s patches is responsible for the induction of T cell-dependent IgA responses. Nat. Immunol. 2013, 14, 372–379. [CrossRef] [PubMed]

34. Davin, J.C.; Coppo, R. Henoch-Schonlein purpura nephritis in children. Nat. Rev. Nephrol. 2014, 10, 563–573. [CrossRef] [PubMed]

35. Hirata, K.; Turner, J.E.; Villa, M.; Duarte, J.H.; Demengeot, J.; Steinmetz, O.M.; Stockinger, B. Plasticity of Th17 cells in Peyer’s patches is responsible for the induction of T cell-dependent IgA responses. Nat. Immunol. 2013, 14, 372–379. [CrossRef] [PubMed]

36. Davin, J.C.; Coppo, R. Henoch-Schonlein purpura nephritis in children. Nat. Rev. Nephrol. 2014, 10, 563–573. [CrossRef] [PubMed]

37. Hirata, K.; Turner, J.E.; Villa, M.; Duarte, J.H.; Demengeot, J.; Steinmetz, O.M.; Stockinger, B. Plasticity of Th17 cells in Peyer’s patches is responsible for the induction of T cell-dependent IgA responses. Nat. Immunol. 2013, 14, 372–379. [CrossRef] [PubMed]

38. Long, Q.X.; Liu, B.Z.; Deng, H.J.; Wu, G.C.; Deng, K.; Chen, Y.K.; Liao, P.; Qiu, J.F.; Lin, Y.; Cai, X.F.; et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat. Med. 2020, 26, 845–848. [CrossRef]
39. Thevarajan, I.; Nguyen, T.H.O.; Koutsakos, M.; Druce, J.; Caly, L.; van de Sandt, C.E.; Jia, X.; Nicholson, S.; Catton, M.; Cowie, B.; et al. Breadth of concomitant immune responses prior to patient recovery: A case report of non-severe COVID-19. Nat. Med. 2020, 26, 453–455. [CrossRef]

40. Juno, J.A.; Tan, H.X.; Lee, W.S.; Reynaldi, A.; Kelly, H.G.; Wragg, K.; Esterbauer, R.; Kent, H.E.; Batten, C.J.; Mordant, F.L.; et al. Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. Nat. Med. 2020, 26, 1428–1434. [CrossRef]

41. Shaan Lakshmanappa, Y.; Elizaldi, S.R.; Roh, J.W.; Schmidt, B.A.; Carroll, T.D.; Weaver, K.D.; Smith, J.C.; Verma, A.; Deere, J.D.; Dutra, J.; et al. SARS-CoV-2 induces robust germinal center CD4 T follicular helper cell responses in rhesus macaques. Nat. Commun. 2021, 12, 541. [CrossRef] [PubMed]

42. Lipsitch, M.; Grad, Y.H.; Sette, A.; Crotty, S. Cross-reactive memory T cells and herd immunity to SARS-CoV-2. Nat. Rev. Immunol. 2020, 20, 709–713. [CrossRef] [PubMed]

43. Rodda, I.B.; Netland, J.; Shehata, L.; Pruner, K.B.; Morawski, P.A.; Thouvenel, C.D.; Takehara, K.K.; Eggenberger, J.; Hemann, E.A.; Waterman, H.R.; et al. Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19. Cell 2021, 184, 169–183.e17. [CrossRef] [PubMed]

44. Dan, J.M.; Mateus, J.; Kato, Y.; Hastie, K.M.; Yu, E.D.; Faliti, C.E.; Grifoni, A.; Ramirez, S.I.; Haupt, S.; Frazier, A.; et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science 2021, 371, eabf4063. [CrossRef] [PubMed]

45. Gom, F.; Dai, Y.; Zheng, T.; Cheng, L.; Zhao, D.; Wang, H.; Liu, M.; Pei, H.; Jin, T.; Yu, D.; et al. Peripheral CD4+ T cell subsets and antibody response in COVID-19 convalescent individuals. J. Clin. Invest. 2020, 130, 6588–6599. [CrossRef]

46. Mathew, D.; Giles, J.R.; Baxter, A.E.; Oldridge, D.A.; Greenplate, A.R.; Wu, J.E.; Alano, C.; Kuri-Cervantes, L.; Pampena, M.B.; D’Andrea, K.; et al. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science 2020, 369, eabe8511. [CrossRef]

47. Zhang, J.; Wu, Q.; Liu, Z.; Wang, Q.; Wu, J.; Hu, Y.; Bai, T.; Xie, T.; Huang, M.; Wu, T.; et al. Spike-specific circulating T follicular helper cell and cross-neutralizing antibody responses in COVID-19-convalescent individuals. Nat. Microbiol. 2021, 6, 51–58. [CrossRef]

48. Duan, Y.Q.; Ao, Q.L.; Xu, S.P.; Kuang, D.; Liu, Q.; Yan, B.; Zhou, Y.W.; et al. Deficiency of Tfh Cells and Germinal Center in Deceased COVID-19 Patients. Curr. Med. Sci. 2020, 40, 618–624. [CrossRef]

49. Kaneko, N.; Kuo, H.H.; Boucau, J.; Farmer, J.R.; Allard-Chamard, H.; Mahajan, V.S.; Datema, J.; Stenstrom, K.; Semmink, L.; et al. Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19. Cell 2020, 183, 143–157 e113.50. [CrossRef]

50. Lee, J.H.; Sutton, H.; Cottrell, C.A.; Chung, N.; Olorunfemi, G.; McLaughlin, M.S.; et al. Rejuvenating conventional dendritic cells and T follicular helper cell formation after vaccination. J. Infect. Dis. 2020, 221, 21–32. [CrossRef]

51. Mathew, D.; Giles, J.R.; Baxter, A.E.; Oldridge, D.A.; Greenplate, A.R.; Wu, J.E.; Alanio, C.; Kuri-Cervantes, L.; Pampena, M.B.; D’Andrea, K.; et al. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science 2020, 369, eabe8511. [CrossRef]

52. Lederer, K.; Bettini, E.; Parvathaneni, K.; Painter, M.M.; Agarwal, D.; Lundgreen, K.A.; Weirick, M.; Muralidharan, K.; Castano, D.; Goel, R.R.; et al. Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals. Cell 2022, 185, 1008–1024 e1015. [CrossRef] [PubMed]

53. Cavazzoni, C.B.; Hanson, B.L.; Podesta, M.A.; Bechu, E.D.; Clement, R.L.; Zhang, H.; Daccache, J.; Rees, M.; et al. Long-lasting germinal center responses to a priming immunization with continuous proliferation and somatic mutation. bioRxiv 2021. [CrossRef]

54. Mudd, P.A.; Minervina, A.A.; Pogorelyy, M.V.; Turner, J.S.; Kim, W.; Kalaidina, E.; Petersen, J.; Schmitz, A.J.; Lei, T.; Haile, A.; et al. SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans. Cell 2022, 185, 603–613.e5. [CrossRef] [PubMed]

55. Lederer, K.; Bettini, E.; Parvathaneni, K.; Painter, M.M.; Agarwal, D.; Lundgreen, K.A.; Weirick, M.; Muralidharan, K.; Castano, D.; Goel, R.R.; et al. Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals. Cell 2022, 185, 1008–1024 e1015. [CrossRef] [PubMed]

56. Lustig, Y.; Sapir, E.; Regev-Yochay, G.; Cohen, C.; Fluss, R.; Olmer, L.; Indenbaum, V.; Mandelboim, O.; Doolman, R., Amit, S.; et al. Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses. Immunity 2022, 55, 1136–1138. [CrossRef] [PubMed]

57. Wragg, K.M.; Lee, W.S.; Koutsakos, M.; Tan, H.X.; Amarasekara, T.; Reynaldi, A.; Gare, G.; Konstandopoulos, P.; Field, K.R.; Esterbauer, R.; et al. Establishment and recall of SARS-CoV-2 spike epitope-specific CD4(+) T cell memory. Nat. Immunol. 2022, 23, 768–780. [CrossRef]

58. Lederer, K.; Bettini, E.; Parvathaneni, K.; Painter, M.M.; Agarwal, D.; Lundgreen, K.A.; Weirick, M.; Muralidharan, K.; Castano, D.; Goel, R.R.; et al. Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals. Cell 2022, 185, 1008–1024 e1015. [CrossRef] [PubMed]

59. Gupta, S.; Su, H.; Agrawal, S. Immune Response to SARS-CoV-2 Vaccine in 2 Men. Int. Arch. Allergy Immunol. 2022, 183, 350–359. [CrossRef]
60. Lederer, K.; Castano, D.; Gomez Atria, D.; Oguin, T.H., 3rd; Wang, S.; Manzoni, T.B.; Muramatsu, H.; Hogan, M.J.; Amanat, F.; Cherubin, P.; et al. SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germlinal Center Responses Associated with Neutralizing Antibody Generation. *Immunity* 2020, 53, 1281–1295.e5. [CrossRef]

61. Yin, M.; Xiong, Y.; Liang, D.; Hong, Q.; Liu, G.; Zeng, J.; Lian, T.; Huang, J.; Ni, J. Circulating Tfh cell and subsets distribution are associated with low-responsiveness to hepatit B vaccination. *Mol. Med.* 2021, 27, 32. [CrossRef] [PubMed]

62. Garcia-Suarez, J.; de la Cruz, J.; Cedillo, A.; Llamas, P.; Duarte, R.; Jimenez-Yuste, V.; Hernandez-Rivas, J.A.; Gil-Marzo, R.; Kwon, M.; Sanchez-Godoy, P.; et al. Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: Lessons from a large population-based registry study. *J. Hematol. Oncol.* 2020, 13, 133. [CrossRef] [PubMed]

63. Meyts, I.; Bucciol, G.; Quinti, I.; Neven, B.; Fischer, A.; Seoane, E.; Lopez-Granados, E.; Gianelli, C.; Robles-Marhuenda, A.; Jeandel, P.Y.; et al. Coronavirus disease 2019 in patients with inborn errors of immunity: An international study. *J. Allergy Clin. Immunol.* 2021, 147, 520–531. [CrossRef] [PubMed]

64. Heldman, M.R.; Kates, O.S.; Safa, K.; Kotton, C.N.; Georgia, S.J.; Hemmersbach-Miller, M.; Blumberg, E.A.; Multani, A.; et al. Changing trends in mortality among solid organ transplant recipients hospitalized for COVID-19 during the course of the pandemic. *Am. J. Transplant.* 2022, 22, 279–288. [CrossRef] [PubMed]

65. Ponsford, M.J.; Ward, T.J.C.; Stoneham, S.M.; Dallimore, C.M.; Sham, D.; Osman, K.; Barry, S.M.; Holmes, I.R.; Farewell, D. A Systematic Review and Meta-Analysis of Inpatient Mortality Associated with Nosocomial and Community COVID-19 Exposes the Vulnerability of Immunosuppressed Adults. *Front. Immunol.* 2021, 12, 744696. [CrossRef] [PubMed]

66. Hagin, D.; Freund, T.; Navon, M.; Halperin, T.; Adir, D.; Marom, R.; Levi, I.; Benor, S.; Alcalay, Y.; Freund, N.T. Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in adult patients with inborn errors of immunity. *J. Allergy Clin. Immunol.* 2021, 148, 739–749. [CrossRef] [PubMed]

67. Delmonte, O.M.; Bergerson, J.R.E.; Burbelo, P.D.; Durkee-Shock, J.R.; Dobbs, K.; Bosticardo, M.; Keller, M.D.; McDermott, D.H.; Rao, V.K.; Dimitrova, D.; et al. Antibody responses to the SARS-CoV-2 vaccine in individuals with various inborn errors of immunity. *J. Allergy Clin. Immunol.* 2021, 148, 1192–1197. [CrossRef] [PubMed]

68. Hassold, N.; Brichler, S.; Ouedraogo, E.; Leclerc, D.; Carroux, S.; Gater, Y.; Alloui, C.; Carbonnelle, E.; Bouchaud, O.; Mechai, F.; et al. Impaired antibody response to COVID-19 vaccination in advanced HIV infection. *AIDS* 2022, 36, F1–F5. [CrossRef]

69. Spinelli, M.A.; Peluso, M.J.; Lynch, K.L.; Yun, C.; Glidden, D.V.; Henrich, T.J.; Deeks, S.G.; Gandhi, M. Differences in Post-mRNA Vaccination SARS-CoV-2 IgG Concentrations and Surrogate Virus Neutralization Test Response by HIV Status and Type of Vaccine: A Matched Case-Control Observational Study. *Clin. Infect. Dis.* 2021, 75, e916–e919. [CrossRef] [PubMed]

70. Furer, V.; Eviatar, T.; Zisman, D.; Peleg, H.; Paran, D.; Levartovsky, D.; Zisapel, M.; Elalouf, O.; Kaufman, I.; Meidan, R.; et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: A multicentre study. *Ann. Rheum. Dis.* 2021, 80, 1330–1338. [CrossRef] [PubMed]

71. Apostolidis, S.A.; Kakara, M.; Painter, M.M.; Goel, R.R.; Mathew, D.; Lenzi, K.; Rezk, A.; Patterson, K.R.; Espinoza, D.A.; Kadri, J.C.; et al. Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. *Nat. Med.* 2021, 27, 1990–2001. [CrossRef] [PubMed]

72. Painter, M.M.; Mathew, D.; Goel, R.R.; Apostolidis, S.A.; Pattekar, A.; Kuthuru, O.; Baxter, A.E.; Herati, R.S.; Oldridge, D.A.; Gouma, S.; et al. Rapid induction of antigen-specific CD4(+) T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination. *Immunity* 2021, 54, 2133–2142.e3. [CrossRef] [PubMed]

73. Peled, Y.; Ram, E.; Lavee, J.; Segev, A.; Matezki, S.; Wieder-Finesod, A.; Halperin, R.; Mandelboim, M.; Indenbaum, V.; Levy, I.; et al. Third dose of the BNT162b2 vaccine in heart transplant recipients: Immunogenicity and clinical efficacy. *J. Heart Lung. Transplant.* 2022, 41, 148–157. [CrossRef] [PubMed]

74. Benotmane, I.; Gautier, G.; Perrin, P.; Olagne, J.; Cognard, N.; Fai-Kremer, S.; Caillard, S. Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients with Minimal Serologic Response to 2 Doses. *JAMA* 2021, 326, 1063–1065. [CrossRef] [PubMed]

75. Kamar, N.; Abravanel, F.; Marion, O.; Romieu-Moreau, R.; Couat, C.; Del Bello, A.; Izopet, J. Assessment of 4 Doses of SARS-CoV-2 Messenger RNA-Based Vaccine in Recipients of a Solid Organ Transplant. *JAMA Netw. Open.* 2021, 4, e2136030. [CrossRef] [PubMed]

76. Tian, J.H.; Patel, N.; Haupt, R.; Zhou, H.; Weston, S.; Hammond, H.; Logue, J.; Portnoff, A.D.; Norton, J.; Guebre-Xabier, M.; et al. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice. *Nat. Commun.* 2021, 12, 372. [CrossRef]

77. Tan, H.X.; Juno, J.A.; Lee, W.S.; Barber-Axthelm, I.; Kelly, H.G.; Wragg, K.M.; Esterbauer, R.; Amarasena, T.; Mordant, F.L.; Subbarao, K.; et al. Immunogenicity of prime-boost protein subunit vaccine strategies against SARS-CoV-2 in mice and macaques. *Nat. Commun.* 2021, 12, 1403. [CrossRef] [PubMed]

78. Wu, Y.; Huang, X.; Yuan, L.; Wang, S.; Zhang, Y.; Xiong, H.; Chen, R.; Ma, J.; Qi, R.; Nie, M.; et al. A recombinant spike protein subunit vaccine confers protective immunity against SARS-CoV-2 infection and transmission in hamsters. *Sci. Transl. Med.* 2021, 13, eaab1143. [CrossRef] [PubMed]

79. Corbett, K.S.; Flynn, B.; Foulks, K.E.; Francica, J.R.; Boyoglu-Barnum, S.; Werner, A.P.; Flach, B.; O’Connell, S.; Bock, K.W.; Minai, M.; et al. Evaluation of the mRNA-1273 Vaccine for SARS-CoV-2 in Nonhuman Primates. *N. Engl. J. Med.* 2020, 383, 1544–1555. [CrossRef] [PubMed]
80. Xia, S.; Zhang, Y.; Wang, Y.; Wang, H.; Yang, Y.; Gao, G.F.; Tan, W.; Wu, G.; Xu, M.; Lou, Z.; et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: A randomised, double-blind, placebo-controlled, phase 1/2 trial. *Lancet Infect. Dis.* 2021, 21, 39–51. [CrossRef]

81. Zhang, Y.; Zeng, G.; Fan, H.; Li, C.; Hu, Y.; Chu, K.; Han, W.; Chen, Z.; Tang, R.; Yin, W.; et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. *Lancet Infect. Dis.* 2021, 21, 181–192. [CrossRef]

82. Wu, Z.; Hu, Y.; Xu, M.; Chen, Z.; Yang, W.; Jiang, Z.; Li, M.; Jin, H.; Cui, G.; Chen, P.; et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. *Lancet Infect. Dis.* 2021, 21, 803–812. [CrossRef]

83. Ella, R.; Reddy, S.; Jogdand, H.; Sarangi, V.; Ganneru, B.; Prasad, S.; Das, D.; Raju, D.; Praturi, U.; Sapkal, G.; et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: Interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial. *Lancet Infect. Dis.* 2021, 21, 950–961. [CrossRef]

84. Tauzin, A.; Nayrac, M.; Benlarbi, M.; Gong, S.Y.; Gasser, R.; Beaudoin-Bussieres, G.; Brassard, N.; Laumaea, A.; Vezina, D.; Prevost, J.; et al. A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses. *Cell Host Microbe* 2021, 29, 1137–1150.e6. [CrossRef] [PubMed]

85. Lau, D.; Lan, L.Y.; Andrews, S.F.; Henry, C.; Rojas, K.T.; Neu, K.E.; Huang, M.; Huang, Y.; DeKosky, B.; Palm, A.E.; et al. Low CD21 expression defines a population of recent germinal center graduates primed for plasma cell differentiation. *Sci. Immunol.* 2017, 2, eaai8153. [CrossRef] [PubMed]